Bharat Immunologicals & Biologicals Corporation Ltd Stock Analysis

BSE: 524663 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 31-Mar-2023 18:02
22.19 1.00 (4.72%)

DeciZen - Make an Informed Decision on Bharat Immunological

M-Cap below 100cr DeciZen not available

Bharat Immunological Price Chart

P/E Ratio ( SA) :
Market Cap :
95.8 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Bharat Immunologicals & Biologicals Corporation Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Bharat Immunologicals & Biologicals Corporation Ltd is a average quality company.

2. Is Bharat Immunologicals & Biologicals Corporation Ltd undervalued or overvalued?

The key valuation ratios of Bharat Immunologicals & Biologicals Corporation Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Bharat Immunologicals & Biologicals Corporation Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bharat Immunologicals & Biologicals Corporation Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Bharat Immunological:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bharat Immunologicals & Biologicals Corporation Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 15.7%21.6%9.1%-5.8%21.6%-9%-13.3%-16.1%-35.4%-4.2%-
Value Creation Index 0.10.6-0.4-1.40.6-1.6-2.0-2.2-3.5NA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 17320314612812434.883.766.885.378.478
YoY Gr. Rt. %-17.3%-27.9%-12.4%-3%-72%140.4%-20.1%27.7%-8.1%-
Adj EPS 1.110.6-1.41.5-1-1.9-2.4-4.3-2.1-2
YoY Gr. Rt. %--1%-45.2%-352.6%NA-166.9%NANANANA-
BVPS (₹)
Adj Net Profit
Cash Flow from Ops. 31.4-11.97.8-9.4-172.5-
Debt/CF from Ops. 00.1-1.1-100-10.12.3-1.9-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -8.4%-8.8%-2.1%-8.1%
Adj EPS -208.1%-207.4%NANA
BVPS -181.1-168.7-159.3-369.1
Share Price 5.8% 2.4% 55.6% -24.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 12.9116-16.316.6-10.8-23.7-40.3-67.4-13.168.6
Op. Profit Mgn %
Net Profit Mgn %
Debt to Equity 0-0-0.20.3001.10.211.6-12.2-
Working Cap Days 8887130119741592675412852330
Cash Conv. Cycle 21638554612515325053840

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 68.60%

Sales growth has been subdued in last 3 years -2.14%

Sales growth is not so good in last 4 quarters at -37.47%

Latest Financials - Bharat Immunologicals & Biologicals Corporation Ltd.

Standalone Consolidated
TTM EPS (₹) -2 -
TTM Sales (₹ Cr.) 78.4 -
BVPS (₹.) -4.4 -
Reserves (₹ Cr.) -62 -
P/BV -5.00 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 20.50 / 51.80
All Time Low / High (₹) 0.25 / 94.50
Market Cap (₹ Cr.) 95.8
Equity (₹ Cr.) 43.2
Face Value (₹) 10
Industry PE 36.2

Management X-Ray of Bharat Immunological :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Bharat Immunological

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Bharat Immunologicals & Biologicals Corporation Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Bharat Immunological on 31-Mar-2023 18:02 is : 22.19.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Mar-2023 18:02 the market cap of Bharat Immunological stood at ₹ 95.82.
The latest PE ratio of Bharat Immunological as of 31-Mar-2023 18:02 is 0.00.
The latest PB ratio of Bharat Immunological as of 31-Mar-2023 18:02 is -5.00
The 52-week high of Bharat Immunological is ₹ 51.80 and the 52-week low is ₹ 20.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Bharat Immunological is ₹ 78.39 ( Cr.) .

About Bharat Immunologicals & Biologicals Corporation Ltd

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency for the nation with respect to production and supply of high quality polio vaccine, a dream project of the Former Prime Minister Late Rajiv Gandhi.

BIBCOL’s principal mission is to save the lives of millions of children from avoidable disability, through polio vaccination. Since its inception, it has contributed significantly to the eradication of Poliomyelitis in the country through the National Immunization Program. BIBCOL is the pioneer in the field of polio vaccines, capturing 60% of total market share in India. The company has achieved a turnover of Rs.30.53 crores during the fiscal year 2005-2006 and earned a net profit of Rs.88.08 Lakhs. Based on the performance of the company and its world class WHO-cGMP certified infrastructure, highly skilled manpower and constant support from DBT, Government of India, BIBCOL is one among the top 20 Biotech companies in India, as revealed by recent market surveys.

Business area of the company:

The Company's principal activity is to manufacture and supply of oral polio vaccine. It supplies oral polio vaccine to Government of India. Its plant is located in Bulandshahr, Uttar Pradesh.

The live oral polio vaccine (OPV) is a trivalent vaccine containing suspensions of type 1,2 and 3 attenuated poliomyelitis viruses (Sabin strains) prepared in primary moneky kidney cell culture. Each dose contains Poliovirus type 1 = 106.0Poliovirus type 2 = 105.0Poliovirus type 3 = 105.8The vaccine contains stabilizers and traces of antibiotics.Doses: 0.1 ml (two drops)Packing Size: 3 ml vial contains 20 doses of OPVStorage: Vaccine is potent if stored at -20oC for 2 years

The trivalent OPV manufactured by BIBCOL is of excellent quality and complies with the GMP requirements of Shedule M of Drugs & Cosmetics Act of Government of India.


  • 1989 - BIBCOL was established by Department of Biotechnology, Ministry of Science & Technology, Govt.of India as a Central Public Sector Unit and incorporated under the Company’s Act 1956.
  • 1989 - About 30 young scientists and technologists from the field of Microbiology, Immunology, Biotechnology, Biochemistry, Pharmaceutical Sciences and Biochemical Engineering were recruited by DBT and trained in the field of vaccine production and quality control in reputed institutes in India and a specialized training at the Institute of Poliomyelitis and Viral Encephalitis, Moscow, Russia
  • 1994- BIBCOL went public and the shares of the company were listed in Delhi, Mumbai and Kanpur stock exchanges
  • 1996 -The company started formulating OPV from bulk since January 1996
  • 1999 - The company acquired WHO-GMP certification
  • 2000- BIBCOL bagged an order from UNICEF as well as from Ministry of Health and Family Welfare, Govt.of India for a total of 170 million doses
  • 2001 - The company bagged another larger order of 270 million doses from UNICEF as well as from the Ministry of Health & Family Welfare, Govt.of India
  • 2004- Due to the extensive restructuring with in the company, BIBCOL achieved a turn over of Rs.53.25 crore during the fiscal year 2004-2005 and has earned a net profit of 132.44 lacs for the first time against the loss pf Rs.3.14 crore during the previous fiscal year 2003-2004
  • 2005 -For the first time, the company has signed a MoU with DBT for the fiscal year 2005-2006. The OPV plant at Chola, Bulandshahr has supplied about 1016 million doses of OPV to the National Immunization Program so far. During the year 2004-2005, 120 million doses were formulated and supplied to NIP, capturing nearly 60 percent of the total market share of polio vaccines in the country.
  • 2006 - The company has secured a place among the Top 20 Biotech companies in the country through its commendable performance.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now